Drugs

, Volume 71, Issue 9, pp 1179–1191 | Cite as

Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma

Review Article

Abstract

Vascular endothelial growth factor (VEGF)-targeted agents have rapidly been adopted into standard-of-care treatment for renal cell carcinoma (RCC). However, a substantial proportion of patients fail to respond to these agents or experience considerable toxicity. This article reviews the benefits and limitations of currently approved anti-VEGF agents in advanced and metastatic RCC, and the role for newly approved and developmental agents. Sunitinib and bevacizumab plus interferon (IFN)-α have demonstrated significant improvements in progression-free survival (PFS) compared with IFNα in treatment-naïve patients. A PFS benefit has also been shown with sorafenib versus placebo second-line to cytokine therapy. However, no anti-VEGF agent has shown a significant overall survival benefit. Anti-VEGF therapy is generally well tolerated, but a number of key adverse events, including dermatological, mucosal and constitutional symptoms, may limit treatment compliance and success. Pazopanib is a recently approved, highly selective anti-VEGF agent that shows benefit in PFS over IFNα, with low rates of treatment-related adverse events and, therefore, may be better tolerated than other currently approved agents. The advent of VEGF-targeted therapy for RCC has greatly improved prospects for patients with advanced or metastatic disease, but more efficacious agents are required that demonstrate a clear survival advantage. Ongoing trials evaluating novel anti-VEGF therapies could establish whether the increased potency and selectivity of these agents results in improved efficacy and tolerability in RCC patients, further improving their prognosis.

Notes

Acknowledgements

This article was supported by an unrestricted educational grant from GlaxoSmithKline. Editorial support for this article by way of manuscript revision and finalising for submission was provided by Medicus International with funding from GlaxoSmithKline. Dr Albiges has no conflict of interest to disclose. Dr Escudier has received honoraria from Bayer, Hoffman LaRoche, Genentech, GlaxoSmithKline, Novartis and Wyeth.

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2): 106–30PubMedCrossRefGoogle Scholar
  2. 2.
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335(12): 865–75PubMedCrossRefGoogle Scholar
  3. 3.
    Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18(3): 581–92PubMedCrossRefGoogle Scholar
  4. 4.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277–300PubMedCrossRefGoogle Scholar
  5. 5.
    Sakamoto S, Ryan AJ, Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 2008; 103(3): 691–708PubMedCrossRefGoogle Scholar
  6. 6.
    Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol 2007; 51(6): 1502–10PubMedCrossRefGoogle Scholar
  7. 7.
    Lanigan D. Prognostic factors in renal cell carcinoma. Br J Urol 1995; 75(5): 565–71PubMedCrossRefGoogle Scholar
  8. 8.
    Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 97(7): 1663–71PubMedCrossRefGoogle Scholar
  9. 9.
    Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 2008; 35(4): 613–25; viiPubMedCrossRefGoogle Scholar
  10. 10.
    Kish JA, Wolf M, Crawford ED, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 1994; 74(3): 916–9Google Scholar
  11. 11.
    Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993; 4(4): 331–2PubMedGoogle Scholar
  12. 12.
    Walsh N, Larkin A, Kennedy S, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 2009; 9: 6PubMedCrossRefGoogle Scholar
  13. 13.
    McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(1): 133–41PubMedCrossRefGoogle Scholar
  14. 14.
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338(18): 1272–8Google Scholar
  15. 15.
    Johannsen M, Brinkmannb OA, Bergmann L, et al. The role of cytokine therapy in metastatic renal cell cancer. Eur Urol Suppl 2007; 6(10): 658–64CrossRefGoogle Scholar
  16. 16.
    Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18(9): 1928–35PubMedGoogle Scholar
  17. 17.
    Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 Suppl. 1: S55–7PubMedGoogle Scholar
  18. 18.
    Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113(2): 293–301PubMedCrossRefGoogle Scholar
  19. 19.
    Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl. 5: 137–9CrossRefGoogle Scholar
  20. 20.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer, V.2.2010, 2010 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf [Accessed 2011 Mar1]
  21. 21.
    Atzpodien J, Kuchler T, Wandert T, et al. Rapid deterioration in quality of life during interleukin-2- and alpha-interferonbased home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer 2003; 89(1): 50–4PubMedCrossRefGoogle Scholar
  22. 22.
    Atzpodien J, Lopez Hanninen E, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995; 13(2): 497–501PubMedGoogle Scholar
  23. 23.
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349(5): 427–34PubMedCrossRefGoogle Scholar
  24. 24.
    Bayer Healthcare. Nexavar: summary of product characteristics, 2006 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf [Accessed 2011 Mar 1]
  25. 25.
    Pfizer. Sutent: summary of product characteristics, 2006 [online]: Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC500057737.pdf [Accessed 2011 Mar1]
  26. 26.
    Roche Pharma AG. Avastin: summary of product characteristics, 2009 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf [Accessed 2011 Mar 1]
  27. 27.
    US Food and Drug Administration. FDA news press release: FDA approves new treatment for advanced form of kidney cancer, 2009 [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187174.htm [Accessed 2011 Mar 1]
  28. 28.
    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584–90PubMedCrossRefGoogle Scholar
  29. 29.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatent of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27(20): 3312–8PubMedCrossRefGoogle Scholar
  30. 30.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125–34PubMedCrossRefGoogle Scholar
  31. 31.
    Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): 5422–8PubMedCrossRefGoogle Scholar
  32. 32.
    Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28(13): 2137–43PubMedCrossRefGoogle Scholar
  33. 33.
    Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103–11PubMedCrossRefGoogle Scholar
  34. 34.
    Escudier B, Bellmunt J, Negrier S, et al. Phase III Trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28(13): 2144–50PubMedCrossRefGoogle Scholar
  35. 35.
    Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28(6): 1061–8PubMedCrossRefGoogle Scholar
  36. 36.
    European Association of Urology. Guidelines on renal cell carcinoma [online]. Available from URL: http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf [Accessed 2011 Mar 1]
  37. 37.
    Sternberg C, Hawkins R, Szczylik C, et al. Randomized double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): final overall survival (OS) results [abstract]. Ann Oncol 2010; 21 Suppl. 8: viii10CrossRefGoogle Scholar
  38. 38.
    Houk HE, Bello CL, Michaelson MD, et al. Exposureresponse of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach [abstract no. 5024]. J Clin Oncol (Meet Abstr) 2007; 25 (241 Suppl.): 5024Google Scholar
  39. 39.
    Houk BE, Bello CL, Kang D, et al. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU 12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15(7): 2497–506PubMedCrossRefGoogle Scholar
  40. 40.
    Hawkins RE. Quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial. 15th Congress of the European Cancer Organisation; 2009 Sep 20–24; BerlinGoogle Scholar
  41. 41.
    Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13(10): 1084–96PubMedCrossRefGoogle Scholar
  42. 42.
    Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009; 35(3): 297–307PubMedCrossRefGoogle Scholar
  43. 43.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115–24PubMedCrossRefGoogle Scholar
  44. 44.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-related fatigue V.1.2009 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf [Accessed 2011 Mar 1]
  45. 45.
    Ahlberg K, Ekman T, Gaston-Johansson F, et al. Assessment and management of cancer-related fatigue in adults. Lancet 2003; 362(9384): 640–50PubMedCrossRefGoogle Scholar
  46. 46.
    Huggins RH, Kuzel TM, Anderson RT, et al. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL) [abstract no. 16122]. J Clin Oncol (Meet Abstr) 2008; 26 (15 Suppl.): 680sGoogle Scholar
  47. 47.
    Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370(9604): 2011–9PubMedCrossRefGoogle Scholar
  48. 48.
    Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112(11): 2500–8PubMedCrossRefGoogle Scholar
  49. 49.
    Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26(32): 5204–12PubMedCrossRefGoogle Scholar
  50. 50.
    Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19(9): 1613–8PubMedCrossRefGoogle Scholar
  51. 51.
    Cella D, Michaelson MD, Cappelleri JC, et al. Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): final results [abstract no. 6529]. J Clin Oncol (Meet Abstr) 2009; 27 (15 Suppl.): 6529Google Scholar
  52. 52.
    McCann L, Amit O, Pandite L, et al. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC). Abstract and presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium; 2010 Mar 5–7; San Francisco, CAGoogle Scholar
  53. 53.
    Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101(10): 1717–23PubMedCrossRefGoogle Scholar
  54. 54.
    Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors [abstract no. 3012]. J Clin Oncol (Meet Abstr) 2005; 23 (16 Suppl.): 3012Google Scholar
  55. 55.
    Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26(1): 127–32PubMedCrossRefGoogle Scholar
  56. 56.
    Kumar R, Knick VB, Rudolph SK, et al. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6(7): 2012–21PubMedCrossRefGoogle Scholar
  57. 57.
    Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9(1): 327–37PubMedGoogle Scholar
  58. 58.
    GlaxoSmithKline. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ), 2009 [ClinicalTrials.gov identifier NCT00720941]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Apr 1]
  59. 59.
    GlaxoSmithKline. Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES), 2010 [ClinicalTrials.gov identifier NCT01064310]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 1]
  60. 60.
    Goldstein R, Pickering L, Larkin J. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? Expert Rev Anticancer Ther 2010; 10(10): 1545–57PubMedCrossRefGoogle Scholar
  61. 61.
    Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008; 14(22): 7272–83PubMedCrossRefGoogle Scholar
  62. 62.
    Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8(11): 975–84PubMedCrossRefGoogle Scholar
  63. 63.
    Rixe O, Dutcher J, Motzer R, et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC) [abstract no. 5045]. J Clin Oncol (Meet Abstr) 2009; 27 (15 Suppl.): 5045Google Scholar
  64. 64.
    Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23(24): 5474–83PubMedCrossRefGoogle Scholar
  65. 65.
    Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27(27): 4462–8PubMedCrossRefGoogle Scholar
  66. 66.
    Pfizer. Axitinib (AG 013736) as second line therapy for metastatic renal cell cancer, 2008 [ClinicalTrials.gov identifier NCT00678392]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 1]
  67. 67.
    Pfizer. Pfizer announces positive phase 3 trial results for axitinib in patients with previously-treated metastatic renal cell carcinoma (mRCC) [online]. Available from URL: http://www.pfizer.com/news/press_releases/pfizer_press_release_archive.jsp#guid=19882&source=RSS_2010&page=2 [Accessed 2011 Mar 1]
  68. 68.
    Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006; 66(18): 9134–42PubMedCrossRefGoogle Scholar
  69. 69.
    De Luca A, Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 2010; 13(9): 636–45PubMedGoogle Scholar
  70. 70.
    Bhargava P, Esteves B, Nosov DA, et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC) [abstract no. 5032]. J Clin Oncol (Meet Abstr) 2009; 27 (15 Suppl.): 5032Google Scholar
  71. 71.
    Bhargava P, Esteves B, Al-Adhami M, et al. Effect of hypertension, nephrectomy, and prior treatment on the efficacy of tivozanib (AV-951) in a phase II randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC). Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium; 2010 Mar 5–7; San Francisco, CA [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30931 [Accessed 2011 Mar 1]
  72. 72.
    Kabbinavar FF, Srinivas S, Hauke RJ, et al. A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC) [abstract no. 330]. J Clin Oncol (Meet Abstr) 2011; 29 Suppl. 7: 330Google Scholar
  73. 73.
    AVEO Pharmaceuticals, Inc. A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1) 2011 [ClinicalTrials.gov identifier NCT01030783]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 1]
  74. 74.
    Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65(10): 4389–400PubMedCrossRefGoogle Scholar
  75. 75.
    Sridhar SS, Mackenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC): a phase II trial of the PMH Consortium [abstract no. 5047]. J Clin Oncol (Meet Abstr) 2008; 26 (18 Suppl.): 5047Google Scholar
  76. 76.
    Mulders P, Hawkins RE, Nathan P. Final results of a phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC) [abstract no. 49LBA]. Eur J Cancer Suppl 2009; 7 (21)Google Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Department of Medical OncologyInstitut Gustave RoussyVillejuifFrance

Personalised recommendations